PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Vivek Narayan(Hospital of the University of Pennsylvania), Naomi B. Haas(University of Pennsylvania)
Cited by 491
Related Papers
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
|Journal of Clinical Oncology|1997|273